Amyloid-β associated cortical thinning in clinically normal elderly

Annals of Neurology

Volumn 69, Issue 6, 2011, Pages 1032-1042

  Becker, J Alex ^a   Hedden, Trey ^a   Carmasin, Jeremy ^a   Maye, Jacqueline ^a   Rentz, Dorene M ^a   Putcha, Deepti ^a   Fischl, Bruce ^a,b   Greve, Douglas N ^a   Marshall, Gad A ^a   Salloway, Stephen ^c,d   Marks, Donald ^e   Buckner, Randy L ^a,f,g   Sperling, Reisa A ^a   Johnson, Keith A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BROWN UNIVERSITY   (United States)

^d BUTLER HOSPITAL   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD UNIVERSITY   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX THICKNESS; BRAIN SIZE; COGNITIVE DEFECT; FEMALE; GERIATRIC PATIENT; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; THICKNESS;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; BRAIN MAPPING; CEREBRAL CORTEX; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; STATISTICS AS TOPIC; THIAZOLES;

EID: 79959405630     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22333     Document Type: Article

References (76)

1. Price JL, Morris JC., Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-368. (Pubitemid 29120041)
2. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365.
3. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004; 62: 925-931. (Pubitemid 38435780)
4. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452. (Pubitemid 44214969)
5. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866. (Pubitemid 44684508)
6. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-680. (Pubitemid 351294719)
7. Hyman BT, Flory JE, Arnold SE, et al. Quantitative assessment of ALZ-50 immunoreactivity in Alzheimer's disease. J Geriatr Psychiatry Neurol 1991; 4: 231-235.
8. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991; 1: 103-116.
9. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319. (Pubitemid 38269583)
10. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49: 786-794. (Pubitemid 27428023)
11. Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009; 132: 2048-2057.
12. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004; 14: 11-22. (Pubitemid 38018050)
13. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988; 23: 138-144. (Pubitemid 18081451)
14. Arriagada PV, Marzloff K, Hyman BT., Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992; 42: 1681-1688.
15. Bennett DA, Schneider JA, Wilson RS, et al. Education modifies the association of amyloid but not tangles with cognitive function. Neurology 2005; 65: 953-955. (Pubitemid 41362153)
16. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517.
17. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903-910.
18. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63: 178-188.
19. Hedden T, Van Dijk KR, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009; 29: 12686-12694.
20. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469-1475.
21. Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2010; 67: 584-587.
22. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-2844. (Pubitemid 350033975)
23. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010; 67: 353-364.
24. Fischl B, Dale AM,. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000; 97: 11050-11055.
25. Lerch JP, Pruessner JC, Zijdenbos A, et al. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex 2005; 15: 995-1001. (Pubitemid 40848068)
26. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006; 31: 968-980. (Pubitemid 44183792)
27. Vemuri P, Gunter JL, Senjem ML, et al. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008; 39: 1186-1197.
28. Scahill RI, Schott JM, Stevens JM, et al. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A 2002; 99: 4703-4707. (Pubitemid 34286048)
29. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009; 19: 497-510.
30. Bakkour A, Morris JC, Dickerson BC., The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009; 72: 1048-1055.
31. Davatzikos C, Xu F, An Y, et al. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain 2009; 132: 2026-2035.
32. Du AT, Schuff N, Kramer JH, et al. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain 2007; 130: 1159-1166. (Pubitemid 47355598)
33. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132: 1310-1323.
34. Storandt M, Mintun MA, Head D, Morris JC., Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009; 66: 1476-1481.
35. Bourgeat P, Chetelat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127.
36. Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer's disease. Ann Neurol 2010; 67: 317-324.
37. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-7717. (Pubitemid 41208641)
38. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982 -1983; 17: 37-49. (Pubitemid 13123113)
39. Folstein MF, Folstein SE, McHugh PR., "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
40. Morris JC., The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414. (Pubitemid 23346995)
41. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
42. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-234. (Pubitemid 47525398)
43. Vogt BA, Vogt L, Laureys S., Cytology and functionally correlated circuits of human posterior cingulate areas. Neuroimage 2006; 29: 452-466. (Pubitemid 43063302)
44. Hayasaka S, Nichols TE., Validating cluster size inference: random field and permutation methods. Neuroimage 2003; 20: 2343-2356. (Pubitemid 37543644)
45. Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG., MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992; 42: 183-188.
46. Whitwell JL, Shiung MM, Przybelski SA, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008; 70: 512-520. (Pubitemid 351653375)
47. Frisoni GB, Fox NC, Jack CR Jr, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010; 6: 67-77.
48. Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004; 23: 724-738. (Pubitemid 39370623)
49. Gusnard DA, Akbudak E, Shulman GL, Raichle ME., Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci U S A 2001; 98: 4259-4264. (Pubitemid 32249932)
50. Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 2009; 29: 1860-1873.
51. Lustig C, Snyder AZ, Bhakta M, et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A 2003; 100: 14504-14509. (Pubitemid 37499266)
52. Daselaar SM, Prince SE, Cabeza R., When less means more: deactivations during encoding that predict subsequent memory. Neuroimage 2004; 23: 921-927. (Pubitemid 39446526)
53. Wagner AD, Shannon BJ, Kahn I, Buckner RL., Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci 2005; 9: 445-453. (Pubitemid 41208254)
54. Andrews-Hanna JR, Snyder AZ, Vincent JL, et al. Disruption of large-scale brain systems in advanced aging. Neuron 2007; 56: 924-935. (Pubitemid 350181355)
55. Fox NC, Warrington EK, Rossor MN., Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet 1999; 353: 2125 (Pubitemid 29278484)
56. Kaye JA, Swihart T, Howieson D, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997; 48: 1297-1304. (Pubitemid 27240552)
57. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-2309.
58. Bennett DA, Schneider JA, Wilson RS, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004; 61: 378-384. (Pubitemid 38327357)
59. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
60. Gomez-Isla T, Price JL, McKeel DW Jr, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491-4500. (Pubitemid 26243044)
61. Walsh DM, Selkoe DJ., A beta oligomers-a decade of discovery. J Neurochem 2007; 101: 1172-1184.
62. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
63. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007; 130: 2607-2615. (Pubitemid 47511709)
64. Rosen RF, Ciliax BJ, Wingo TS, et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol 2010; 119: 221-233.
65. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 1304-1309.
66. Jack CR Jr, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998; 51: 993-999. (Pubitemid 28473390)
67. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008; 42: 559-567.
68. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex 2010; 20: 2069-2079.
69. Braak H, Braak E., Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-357. (Pubitemid 27435070)
70. Salat DH, Buckner RL, Snyder AZ, et al. Thinning of the cerebral cortex in aging. Cereb Cortex 2004; 14: 721-730. (Pubitemid 38856947)
71. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725. (Pubitemid 46763260)
72. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010; 74: 807-815.
73. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122-131.
74. Hyman BT., The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies. Neurobiol Aging 1997; 18: S27-S32. (Pubitemid 27454693)
75. Wegiel J, Wisniewski HM, Morys J, et al. Neuronal loss and beta-amyloid removal in the amygdala of people with Down syndrome. Neurobiol Aging 1999; 20: 259-269. (Pubitemid 29525411)
76. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372.